Clinical Trials Logo

Vasovagal Syncope (VVS) clinical trials

View clinical trials related to Vasovagal Syncope (VVS).

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02558972 Active, not recruiting - Clinical trials for Postural Tachycardia Syndrome (POTS)

Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)

Start date: September 2015
Phase: Phase 2
Study type: Interventional

Vasovagal syncope (VVS, simple faint) is the most common cause of transient loss of consciousness and represents the acute episodic form of orthostatic intolerance (OI). Postural tachycardia syndrome (POTS) is the common chronic form of OI. Both are defined by debilitating symptoms and signs while upright relieved by recumbency. Northera should therefore improve both sympathetic splanchnic arterial vasoconstriction and sympathetic splanchnic venoconstriction in POTS and VVS, and may represent an ideal drug to improve the orthostatic response in POTS and VVS.